Evidence map›Paper›PMID 26392359›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2015

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.

Insaf Fkih M'hamed, Maud Privat, Flora Ponelle, Frédérique Penault-Llorca, Abderraouf Kenani, Yves-Jean Bignon

Open access · hybridAbstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis.International journal of molecular sciences · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Insaf Fkih M'hamedDépartement d'Oncogénétique, Centre Jean Perrin, BP 392, 63011, Clermont-Ferrand, France.
Maud PrivatDépartement d'Oncogénétique, Centre Jean Perrin, BP 392, 63011, Clermont-Ferrand, France.
Flora PonelleDépartement d'Oncogénétique, Centre Jean Perrin, BP 392, 63011, Clermont-Ferrand, France.
Frédérique Penault-LlorcaEA4677 ERTICA, Université d'Auvergne, Clermont-Ferrand, France.
Abderraouf KenaniFaculté de médecine de Monastir, Laboratoire de Biochimie, Unité de recherche UR 12ES08 "Signalisation Cellulaire et Pathologies", 5019, Monastir, Tunisie.
Yves-Jean BignonDépartement d'Oncogénétique, Centre Jean Perrin, BP 392, 63011, Clermont-Ferrand, France. Yves-Jean.Bignon@cjp.fr.
Université Clermont Auvergne · FRCentre Jean Perrin · FRLaboratoire de Biochimie · FRUniversity of Monastir · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFamilial triple-negative breast cancers are often linked to mutations in the BRCA1 tumor suppressor gene. In sporadic triple-negative breast cancers BRCA1 is frequently inactivated at the transcriptional level, and it has been reported that this inactivation may be brought about by promoter methylation. More recently, it was found that BRCA1 may also be regulated at the post-transcriptional level by miRNAs. Here, we explored the expression of putative BRCA1-regulating miRNAs in sporadic human triple-negative breast cancer cells.

methodsNine sporadic human breast cancer-derived cell lines and one benign breast epithelium-derived cell line were assessed for their hormone receptor, growth factor receptor and cytokeratin status by immunocytochemistry. The expression of 5 selected miRNAs predicted to target BRCA1 was assessed using qRT-PCR in the 10 cell lines. In addition, expression profiles of 84 known breast cancer-associated miRNAs were established in these 10 cell lines using PCR Array and qRT-PCR, respectively. The putative role of pre-selected candidate miRNAs in breast cancer development was assessed through exogenous expression of these miRNAs and their anti-miRNAs ('antagomirs') in MDA-MB-231 and MCF7 breast cancer-derived cells.

resultsBased on our expression profiling results, four candidate miRNAs (miR-10b, miR-26a, miR-146a and miR-153) were selected as being potentially involved in triple-negative breast cancer development. Exogenous expression assays revealed that miR-10b and miR-26a, but not miR-146a, can down-regulate the expression of BRCA1 in both triple-negative MDA-MB-231 and luminal epithelial MCF7 breast cancer-derived cells, whereas miR-153 could down-regulate BRCA1 expression only in MCF7 cells. In silico analysis of The Cancer Genome Atlas (TCGA) data confirmed that miR-146a is significantly higher expressed in triple-negative breast tumors compared to other (non triple-negative) breast tumors.

conclusionOur work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression.

Indexed as

AlgorithmsBiomarkers, TumorBRCA1 ProteinCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMicroRNAsPolymerase Chain ReactionTranscriptomeTransfectionTriple Negative Breast NeoplasmsBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanMicroRNAsMIRN10 microRNA, humanMIRN146 microRNA, humanMIRN153 microRNA, humanMIRN26 microRNA, humanBRCA1Human triple-negative breast cancer cellsMicroRNAsRegulation

Identifiers

PMID26392359
PMCPMC4653246
OpenAlexW1962083355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.